Saamya Biotech (India) Ltd - Stock Valuation and Financial Performance

BSE: 532905 | NSE: | Pharmaceuticals & Drugs | Small Cap

BSE Share Price
Not Listed

DeciZen - make an informed investing decision on Saamya Biotech (I)

M-Cap below 100cr DeciZen not available

Saamya Biotech (India) stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
4.9 Cr.
52-wk low:
2
52-wk high:
2.1

Is an attractive stock to invest in?

1. Is a good quality company?

Data is not available for this company.

2. Is undervalued or overvalued?

No data found

3. Is a good buy now?

No data found

10 Year X-Ray of Saamya Biotech (I):

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.

Value Creation

Value Creation Index Colour Code Guide

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
ROCE % 0%0%0%0.1%0.7%1.2%-1.1%0.4%-2.1%-1.6%-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 0002.416.323.1313.428.814.40
Sales YoY Gr.-NANANA592.8%41.7%-87.1%348.3%115.3%-50%-
Adj EPS 00000.1-0.1-0.20.1-0.3-0.2-0
YoY Gr.-NANANA700%-187.5%NANA-660%NA-
BVPS (₹) 1010101010.111.911.811.811.511.411.3
Adj Net
Profit
00000.2-0.2-0.40.1-0.7-0.50
Cash Flow from Ops. -1-2.2-3.90.4-0.7-1-0.2-0.20.60.1-
Debt/CF from Ops. -0.6-0.5-00.4-0.3-0.4-1.8-205.839.5-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales NA-2.4%69.1%-50%
Adj EPS NA-221.3%NANA
BVPS1.5%2.5%-1.2%-1.6%
Share Price - - - -

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16TTM
Return on
Equity %
0000.10.6-0.5-1.10.4-2.4-1.8-0.1
Op. Profit
Mgn %
0001.42.62.5-9.12.50.8-0.9NAN
Net Profit
Mgn %
0000.91.1-0.8-12.61-2.4-3.6-INF
Debt to
Equity
0.10000000.20.10.1-
Working Cap
Days
0002,1591452332,5994803531,1460
Cash Conv.
Cycle
00013133224232990

Recent Performance Summary

No data to display

Return on Equity has declined versus last 3 years average to %

Sales growth has been subdued in last 3 years %

Sales growth is not so good in last 4 quarters at %

Latest Financials - Saamya Biotech (India) Ltd.

Standalone Consolidated
TTM EPS (₹) -0 -
TTM Sales (₹ Cr.) 0 -
BVPS (₹.) 11.3 -
Reserves (₹ Cr.) 3 -
P/BV 0.17 -
PE 0.00 -
From the Market
52 Week Low / High (₹) 1.97 / 2.07
All Time Low / High (₹) 0.98 / 31.95
Market Cap (₹ Cr.) 4.9
Equity (₹ Cr.) 24.9
Face Value (₹) 10
Industry PE 48.2

Management X-Ray of Saamya Biotech (I):

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Saamya Biotech (I)

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Sales0002.3516.2823.072.9813.3628.7714.40
Operating Expenses 0002.3115.9822.493.2913.0828.5314.53
Manufacturing Costs00000.030.030.020.0200
Material Costs0002.2015.4721.322.8112.7328.3814.37
Employee Cost 0000.010.080.140.060.040.040.04
Other Costs 0000.100.4010.410.290.110.13
Operating Profit 0000.030.300.58-0.310.280.24-0.13
Operating Profit Margin (%) ---1.3%1.9%2.5%-10.3%2.1%0.8%-0.9%
Other Income 000000.66000.030.11
Interest 00000.040.810.030.0200
Depreciation 00000.070.070.070.1210.92
Exceptional Items 0000000000
Profit Before Tax 0000.030.190.35-0.410.15-0.73-0.94
Tax 0000.010.100.08-0.010.06-0.05-0.50
Profit After Tax 0000.020.090.28-0.400.10-0.68-0.44
PAT Margin (%) ---0.9%0.5%1.2%-13.4%0.7%-2.4%-3.1%
Adjusted EPS (₹)0.00.00.00.00.00.1-0.20.0-0.3-0.2
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16

Equity and Liabilities

Shareholders Fund 8.0823.0923.0923.1123.2029.6829.2829.3828.7028.26
Share Capital 8.0823.0923.0923.0923.0924.8824.8824.8824.8824.88
Reserves 0000.020.114.804.404.493.813.37
Minority Interest0000000000
Debt0.5710.110.160.220.380.354.433.633.24
Long Term Debt0.5710.110.160.220.380.354.433.633.24
Short Term Debt0000000000
Trade Payables00.010.042.267.2515.9818.5410.0339.8346.80
Others Liabilities 0.941.781.547.809.164.654.960.740.750.51
Total Liabilities 9.5925.8824.7833.3339.8350.6953.1344.5772.9178.81

Fixed Assets

Gross Block0.350.610.701.641.411.641.5612.0911.8511.65
Accumulated Depreciation00000.050.120.180.291.192.11
Net Fixed Assets0.350.610.701.641.361.521.3811.8010.669.54
CWIP 00027.8128.7529.0229.3418.2518.2518.25
Investments 08.230.010.01000000
Inventories0000000000
Trade Receivables0002.358.1818.3621.0113.1643.1750.18
Cash Equivalents 0.010.180.050.070.040.040.010.020.020.02
Others Assets9.2316.8624.021.451.511.751.391.340.820.82
Total Assets 9.5925.8824.7833.3339.8350.6953.1344.5772.9178.81

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Cash Flow From Operating Activity -1.03-2.22-3.850.39-0.74-1.01-0.19-0.220.620.08
PBT 0000.030.190.35-0.410.15-0.73-0.94
Adjustment 00000.240.100.130.190.970.81
Changes in Working Capital -1.03-2.22-3.850.35-1.17-1.460.09-0.560.380.21
Tax Paid 0000000000
Cash Flow From Investing Activity -0.44-13.654.70-6.18-0.85-0.51-0.290.510.170.31
Capex -0.34-0.27-0.09-0.940.08-0.240.03-10.580.170.31
Net Investments 0-8.238.2200.0100000
Others -0.10-5.15-3.44-5.24-0.94-0.27-0.3211.0900
Cash Flow From Financing Activity 1.4716.04-0.985.811.561.520.45-0.28-0.80-0.39
Net Proceeds from Shares 0.9115.61-0.095.771.533.180.48000
Net Proceeds from Borrowing 000000.15-0.03-0.30-0.80-0.39
Interest Paid 0000-0.04-0.02-0.02-0.0200
Dividend Paid 0000000000
Others 0.570.43-0.890.040.07-1.790.020.0400
Net Cash Flow 00.17-0.130.02-0.040.01-0.030.0100
PARTICULARSMar'07Mar'08Mar'09Mar'10Mar'11Mar'12Mar'13Mar'14Mar'15Mar'16
Ratios
ROE (%)0000.090.381.05-1.360.33-2.34-1.55
ROCE (%)0000.110.743.54-1.110.5-2.22-2.93
Asset Turnover Ratio0000.080.460.510.060.290.510.2
PAT to CFO Conversion(x)-INF-INF-INF19.5-8.22-3.61N/A-2.2N/AN/A
Working Capital Days
Receivable Days0003651132082,4094453401,127
Inventory Days0000000000
Payable Days0001901121992,2464103211,101

Saamya Biotech (India) Ltd Stock News

Saamya Biotech (India) Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Saamya Biotech (I) on 01-Jan-1970 05:30 is ₹0.00.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 01-Jan-1970 05:30 the market cap of Saamya Biotech (I) stood at ₹4.90.
The latest P/E ratio of Saamya Biotech (I) as of 01-Jan-1970 05:30 is 0.00.
The latest P/B ratio of Saamya Biotech (I) as of 01-Jan-1970 05:30 is 0.17.
The 52-week high of Saamya Biotech (I) is ₹2.07 and the 52-week low is ₹1.97.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Saamya Biotech (I) is ₹0.00 ( Cr.) .

About Saamya Biotech (India) Ltd

Saamya Biotech (India) was incorporated as a public limited company on August 13, 2002 and certificate of commencement of business was issued on August 26, 2002. The promoters of the company are Dr. Y. Manivardhan Reddy and Dr. Y. Sonia Reddy and it is engaged in business of manufacturing, import, export and dealing in all types of chemicals pharmaceuticals drugs and intermediates.

Saamya Biotech (India) (SBIL) is a new generation biotechnology company incorporated in India (Hyderabad) with the aim to manufacture and market biopharmaceuticals and recombinant protein products of medical and industrial importance, and also to discover and develop emerging biotech products of far reaching significance. The company proposes to set up world class facilities for the manufacture of fermentation based high value biotech products. The company embarks on developing effective strategies for the production and supply of both bulk and formulations with special focus on life saving drug entities at affordable price.

The company has entered into technology transfer agreement with Biofin laboratories s.r.l Italy for technology know-how to manufacture bio-pharmaceutical ingredients.

The company entered into sales and purchase agreement with Finchimica, Italy on September 18, 2004, in terms of which Finchimica, Italy would buy all the products manufactured by it to the extent of 100%.

Product range off the company includes:

  • Daunomycin
  • Hyaluronic acid (Pharma grade)
  • Tacrolimus and Rapamycin
  • Cyclosporin A, Probiotics
  • Lysergic acid
  • Mycophenolic acid
  • Clavulenic acid
  • Vancomycin
  • Co-enzyme Q10
  • Interferon β
  • Monoclonal antibodies (anti-cancer).
Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.